Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

8.15
-0.5700-6.54%
Post-market: 8.310.1600+1.96%17:08 EDT
Volume:750.44K
Turnover:6.27M
Market Cap:431.58M
PE:-10.48
High:9.19
Open:8.97
Low:8.00
Close:8.72
52wk High:11.61
52wk Low:1.34
Shares:52.96M
Float Shares:41.44M
Volume Ratio:0.71
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.7641
ROE:-55.00%
ROA:-29.30%
PB:4.60
PE(LYR):-10.67

Loading ...

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for Nxc-201

THOMSON REUTERS
·
Jan 28

Immix Biopharma Inc: Final Data Expected This Year Followed by Planned Bla Submission

THOMSON REUTERS
·
Jan 28

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities

Benzinga_recent_news
·
Jan 12

BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing

Reuters
·
Jan 10

Immix Biopharma files $750M mixed securities shelf

TIPRANKS
·
Jan 10

Immix Biopharma Inc - to Offer and Sell up to $750 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Jan 10

Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges

Reuters
·
Jan 10

Immix Biopharma CEO Ilya Rachman Acquires Common Shares

Reuters
·
Dec 11, 2025

Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025

BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Dec 10, 2025

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 09, 2025

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8

THOMSON REUTERS
·
Dec 09, 2025

Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges

Reuters
·
Dec 09, 2025

BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share

Reuters
·
Dec 08, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Dec 08, 2025

Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share

THOMSON REUTERS
·
Dec 08, 2025

Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis

Reuters
·
Dec 08, 2025

at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS
·
Dec 08, 2025

Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis

Reuters
·
Dec 03, 2025

Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer

Reuters
·
Nov 12, 2025